MA28563B1 - 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation - Google Patents

1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation

Info

Publication number
MA28563B1
MA28563B1 MA29429A MA29429A MA28563B1 MA 28563 B1 MA28563 B1 MA 28563B1 MA 29429 A MA29429 A MA 29429A MA 29429 A MA29429 A MA 29429A MA 28563 B1 MA28563 B1 MA 28563B1
Authority
MA
Morocco
Prior art keywords
oxadiazol
modulators
ones
ppar delta
ppar
Prior art date
Application number
MA29429A
Other languages
English (en)
Inventor
Daniel G Mcgarry
Jochen Goerlitzer
Stefanie Keil
Karen Chandross
Jean Merrill
Wolfgang Wendler
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MA28563B1 publication Critical patent/MA28563B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA29429A 2004-04-01 2006-10-31 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation MA28563B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55842004P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
MA28563B1 true MA28563B1 (fr) 2007-04-03

Family

ID=34972960

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29429A MA28563B1 (fr) 2004-04-01 2006-10-31 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation

Country Status (15)

Country Link
US (2) US7638539B2 (fr)
EP (1) EP1781648A2 (fr)
JP (1) JP4813461B2 (fr)
CN (1) CN1956984B (fr)
AU (1) AU2005230838A1 (fr)
BR (1) BRPI0508180A (fr)
CA (1) CA2561230A1 (fr)
IL (1) IL178166A0 (fr)
MA (1) MA28563B1 (fr)
NO (1) NO20064951L (fr)
NZ (1) NZ549823A (fr)
RU (1) RU2365589C2 (fr)
SG (1) SG151336A1 (fr)
WO (1) WO2005097763A2 (fr)
ZA (1) ZA200607852B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509468A (pt) * 2004-04-01 2007-09-11 Aventis Pharma Inc 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
EP1781648A2 (fr) * 2004-04-01 2007-05-09 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones en tant que modulateurs des ppar delta
EP1745014B1 (fr) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Nouveaux composes, leur preparation et leur utilisation
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
MX2007016374A (es) 2005-06-30 2008-03-05 Novo Nordisk As Acidos fenoxiaceticos como activadores ppar delta.
WO2007039177A2 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
EP1979311B1 (fr) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Acides phénoxyacétiques en tant qu'activateurs ppar delta
CA2645719A1 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composes, leur preparation et utilisation
JP2013506687A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
CA2923422C (fr) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie
KR101715127B1 (ko) * 2015-10-30 2017-03-15 한국과학기술연구원 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체
WO2021092279A1 (fr) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Procédés de traitement de maladies de dysmyélinisation/dysmyélinisantes
CN114195777B (zh) * 2020-09-18 2023-06-20 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
CN114195786B (zh) * 2020-09-18 2023-08-22 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
ES2277842T3 (es) * 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1210345B1 (fr) * 1999-09-08 2004-03-03 Glaxo Group Limited Antagonistes ppar oxazole
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
BRPI0509468A (pt) * 2004-04-01 2007-09-11 Aventis Pharma Inc 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
EP1781648A2 (fr) * 2004-04-01 2007-05-09 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones en tant que modulateurs des ppar delta

Also Published As

Publication number Publication date
RU2365589C2 (ru) 2009-08-27
US7872032B2 (en) 2011-01-18
NO20064951L (no) 2006-10-30
US20070099964A1 (en) 2007-05-03
SG151336A1 (en) 2009-04-30
ZA200607852B (en) 2008-07-30
CN1956984A (zh) 2007-05-02
US7638539B2 (en) 2009-12-29
IL178166A0 (en) 2006-12-31
JP2007531764A (ja) 2007-11-08
AU2005230838A1 (en) 2005-10-20
JP4813461B2 (ja) 2011-11-09
RU2006138494A (ru) 2008-05-10
EP1781648A2 (fr) 2007-05-09
US20090275621A1 (en) 2009-11-05
WO2005097763A3 (fr) 2005-12-15
CN1956984B (zh) 2010-06-09
CA2561230A1 (fr) 2005-10-20
BRPI0508180A (pt) 2007-08-07
NZ549823A (en) 2009-12-24
WO2005097763A2 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
IL232313A0 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the aforementioned
MA28563B1 (fr) 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation
ATE540027T1 (de) Tetrahydroindazol-cannabinoidmodulatoren
FR14C0067I2 (fr) Modulateurs c-met et produits d'utilisation
EP1954140A4 (fr) Cetals de glycerol-levulinate et utilisation
EP1971600A4 (fr) Derives d'isoxasole et leur utilisation
EP1858864A4 (fr) Compositions stabilisees d'agents d'alkylation volatils et methodes d'utilisation de ces compositions
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
MA28869B1 (fr) Phenylaminothiazoles substitues, et leur utilisation
EP2171096A4 (fr) Polymorphismes de carboxylestérase-1 etleurs méthodes d'utilisation
ATE542816T1 (de) Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
EP1731506A4 (fr) Derives de 5-hydroxyindol-3-carboxylate et leur utilisation
EP1731547A4 (fr) Composés polymérisables et utilisation de ceux-ci
EP2140883A4 (fr) Nouvelle base pour dispersion solide sèche, dispersion solide contenant la base et composition contenant la dispersion
MA28900B1 (fr) Composes et compositions en tant que modulateurs ppar
EP1846041A4 (fr) Vecteurs de bacteriophage modifie et utilisation de ceux-ci
ATE432701T1 (de) Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren
DE602004021384D1 (de) Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
EP1976548A4 (fr) Fragments de vip et méthodes d'utilisation
EP2304444A4 (fr) Modulateurs de l'interaction entre stat3 et sp1
HUE043668T2 (hu) Szemészeti készítmények és alkalmazásuk
EP1897866A4 (fr) P-trifluoromethylephenylethers substitues, leur preparation et leur utilisation
EP1837382A4 (fr) Composition d'agent de revetement et utilisation de la composition
EP1786431A4 (fr) Preparations de photosensibiliseur ameliorees et utilisation de celles-ci
EP1991058A4 (fr) Francisella atténuée et méthodes d'utilisation